Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD) [Phase 1, Phase 2]

View source ↗

Summary

The document reports a personalized antisense oligonucleotide therapy being studied in one participant with LMNB1-mutant Autosomal Dominant Leukodystrophy (ADLD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Leukodystrophy

Drugs mentioned

• Personalized antisense oligonucleotide therapy for LMNB1-associated Autosomal Dominant Leukodystrophy

Snippet

Sponsor: n-Lorem Foundation | Conditions: Autosomal Dominant Leukodystrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING